Waters Corporation (WAT)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$409.38-1.01%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · WAT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks WAT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 2 guided quarters · 5.6% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Raise full-year 2026 organic constant currency revenue growth guidance to 7-9%, with total reported revenue expected between $6.415B and $6.476B.
Stated as a priority in 3 of last 3 quarters. Full-year 2026 organic constant currency revenue growth guidance was raised from 5.5-7.0% in 2025-Q4 to 7-9% in 2026-Q2. Reported revenue guidance increased from about $6.405B to $6.476B over the same period. Management is delivering on this growth priority with consistent upward revisions.
“The Company is raising all components of its full-year 2026 guidance, given better-than-expected results and broad strengthening in end-market conditions.”
“The Company is raising its full-year 2026 organic, constant currency revenue growth guidance to the range of 6.5% to 8.0%.”
“The Company expects full-year 2026 organic constant currency revenue growth to be in the range of +5.5% to +7.0%.”
Raise full-year 2026 adjusted EPS guidance to $14.45 to $14.65, representing 10-12% growth year-over-year.
Stated as a priority in 3 of last 3 quarters. Full-year 2026 adjusted EPS guidance increased from $14.30-$14.50 in 2025-Q4 to $14.45-$14.65 in 2026-Q2, reflecting 10-12% growth. Management is delivering consistent upward revisions aligned with financial results.
Focus on seamless integration of Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson to realize revenue and cost synergies.
Stated as a priority in 3 of last 3 quarters. Revenue from acquired Biosciences and Diagnostic Solutions businesses increased from $520M in 2026-Q1 to $817M in 2026-Q2, reflecting integration progress and operational improvements. Management reiterates focus on seamless integration and synergy realization, delivering on this priority.
Over the trailing year it converted 2.04x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“The Company is raising its full-year 2026 adjusted EPS guidance to the range of $14.45 to $14.65, reflecting 10-12% growth.”
“The Company is raising its full-year 2026 adjusted EPS guidance to $14.40 to $14.60.”
“The Company expects full-year 2026 non-GAAP EPS to be in the range of $14.30 to $14.50.”
“Our integration continues to gain momentum, while the recovery across our end markets has broadened.”
“Our teams are focused on executing a seamless integration, delivering industry-leading growth.”
“Integration planning is progressing as expected, and we remain highly confident in the achievability of significant cost and revenue synergies.”